LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker ...
CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback